AdvaMed Encourages Risk-Based FDA Approach to Generative AI Medical Devices
OVERVIEWAdvaMed (Advanced Medical Technology Association) has submitted formal comments to FDA encouraging risk-based regulatory approach to generative AI medical devices, arguing that regulatory framework should differentiate between high-risk autonomous AI applications and lower-risk decision-support tools. The position reflects device industry preference for proportionate regulation that doesn't impede innovation. AdvaMed's framework proposes FDA oversight intensity correlate with clinical risk level, with lighter-touch regulation for AI tools with human clinician oversight and stronger requirements for autonomous clinical decision-making systems. The approach aims to balance innovation incentives with patient safety considerations. The FDA is actively soliciting stakeholder input on regulatory approaches, with device manufacturers advocating for risk-based frameworks while clinical and patient safety advocates push for more stringent requirements regardless of risk level. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.